SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Amin Ahmad) "

Search: WFRF:(Amin Ahmad)

  • Result 1-25 of 63
Sort/group result
   
EnumerationReferenceCoverFind
1.
  • Ademuyiwa, Adesoji O., et al. (author)
  • Determinants of morbidity and mortality following emergency abdominal surgery in children in low-income and middle-income countries
  • 2016
  • In: BMJ Global Health. - : BMJ Publishing Group Ltd. - 2059-7908. ; 1:4
  • Journal article (peer-reviewed)abstract
    • Background: Child health is a key priority on the global health agenda, yet the provision of essential and emergency surgery in children is patchy in resource-poor regions. This study was aimed to determine the mortality risk for emergency abdominal paediatric surgery in low-income countries globally.Methods: Multicentre, international, prospective, cohort study. Self-selected surgical units performing emergency abdominal surgery submitted prespecified data for consecutive children aged <16 years during a 2-week period between July and December 2014. The United Nation's Human Development Index (HDI) was used to stratify countries. The main outcome measure was 30-day postoperative mortality, analysed by multilevel logistic regression.Results: This study included 1409 patients from 253 centres in 43 countries; 282 children were under 2 years of age. Among them, 265 (18.8%) were from low-HDI, 450 (31.9%) from middle-HDI and 694 (49.3%) from high-HDI countries. The most common operations performed were appendectomy, small bowel resection, pyloromyotomy and correction of intussusception. After adjustment for patient and hospital risk factors, child mortality at 30 days was significantly higher in low-HDI (adjusted OR 7.14 (95% CI 2.52 to 20.23), p<0.001) and middle-HDI (4.42 (1.44 to 13.56), p=0.009) countries compared with high-HDI countries, translating to 40 excess deaths per 1000 procedures performed.Conclusions: Adjusted mortality in children following emergency abdominal surgery may be as high as 7 times greater in low-HDI and middle-HDI countries compared with high-HDI countries. Effective provision of emergency essential surgery should be a key priority for global child health agendas.
  •  
2.
  • Abbafati, Cristiana, et al. (author)
  • 2020
  • Journal article (peer-reviewed)
  •  
3.
  •  
4.
  • 2021
  • swepub:Mat__t
  •  
5.
  • Feigin, Valery L., et al. (author)
  • Global, regional, and national burden of stroke and its risk factors, 1990-2019 : a systematic analysis for the Global Burden of Disease Study 2019
  • 2021
  • In: Lancet Neurology. - : Elsevier. - 1474-4422 .- 1474-4465. ; 20:10, s. 795-820
  • Journal article (peer-reviewed)abstract
    • Background Regularly updated data on stroke and its pathological types, including data on their incidence, prevalence, mortality, disability, risk factors, and epidemiological trends, are important for evidence-based stroke care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) aims to provide a standardised and comprehensive measurement of these metrics at global, regional, and national levels. Methods We applied GBD 2019 analytical tools to calculate stroke incidence, prevalence, mortality, disability-adjusted life-years (DALYs), and the population attributable fraction (PAF) of DALYs (with corresponding 95% uncertainty intervals [UIs]) associated with 19 risk factors, for 204 countries and territories from 1990 to 2019. These estimates were provided for ischaemic stroke, intracerebral haemorrhage, subarachnoid haemorrhage, and all strokes combined, and stratified by sex, age group, and World Bank country income level. Findings In 2019, there were 12.2 million (95% UI 11.0-13.6) incident cases of stroke, 101 million (93.2-111) prevalent cases of stroke, 143 million (133-153) DALYs due to stroke, and 6.55 million (6.00-7.02) deaths from stroke. Globally, stroke remained the second-leading cause of death (11.6% [10.8-12.2] of total deaths) and the third-leading cause of death and disability combined (5.7% [5.1-6.2] of total DALYs) in 2019. From 1990 to 2019, the absolute number of incident strokes increased by 70.0% (67.0-73.0), prevalent strokes increased by 85.0% (83.0-88.0), deaths from stroke increased by 43.0% (31.0-55.0), and DALYs due to stroke increased by 32.0% (22.0-42.0). During the same period, age-standardised rates of stroke incidence decreased by 17.0% (15.0-18.0), mortality decreased by 36.0% (31.0-42.0), prevalence decreased by 6.0% (5.0-7.0), and DALYs decreased by 36.0% (31.0-42.0). However, among people younger than 70 years, prevalence rates increased by 22.0% (21.0-24.0) and incidence rates increased by 15.0% (12.0-18.0). In 2019, the age-standardised stroke-related mortality rate was 3.6 (3.5-3.8) times higher in the World Bank low-income group than in the World Bank high-income group, and the age-standardised stroke-related DALY rate was 3.7 (3.5-3.9) times higher in the low-income group than the high-income group. Ischaemic stroke constituted 62.4% of all incident strokes in 2019 (7.63 million [6.57-8.96]), while intracerebral haemorrhage constituted 27.9% (3.41 million [2.97-3.91]) and subarachnoid haemorrhage constituted 9.7% (1.18 million [1.01-1.39]). In 2019, the five leading risk factors for stroke were high systolic blood pressure (contributing to 79.6 million [67.7-90.8] DALYs or 55.5% [48.2-62.0] of total stroke DALYs), high body-mass index (34.9 million [22.3-48.6] DALYs or 24.3% [15.7-33.2]), high fasting plasma glucose (28.9 million [19.8-41.5] DALYs or 20.2% [13.8-29.1]), ambient particulate matter pollution (28.7 million [23.4-33.4] DALYs or 20.1% [16.6-23.0]), and smoking (25.3 million [22.6-28.2] DALYs or 17.6% [16.4-19.0]). Interpretation The annual number of strokes and deaths due to stroke increased substantially from 1990 to 2019, despite substantial reductions in age-standardised rates, particularly among people older than 70 years. The highest age-standardised stroke-related mortality and DALY rates were in the World Bank low-income group. The fastest-growing risk factor for stroke between 1990 and 2019 was high body-mass index. Without urgent implementation of effective primary prevention strategies, the stroke burden will probably continue to grow across the world, particularly in low-income countries.
  •  
6.
  •  
7.
  •  
8.
  • Sepanlou, Sadaf G., et al. (author)
  • The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017
  • 2020
  • In: The Lancet Gastroenterology & Hepatology. - 2468-1253. ; 5:3, s. 245-266
  • Journal article (peer-reviewed)abstract
    • Background Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories. Methods We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the basis of hospital and claims data. Disability-adjusted life-years (DALYs) were calculated as the sum of years of life lost due to premature death and years lived with disability. Estimates are presented as numbers and age-standardised or age-specific rates per 100 000 population, with 95% uncertainty intervals (UIs). All estimates are presented for five causes of cirrhosis: hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis (NASH), and other causes. We compared mortality, prevalence, and DALY estimates with those expected according to the Socio-demographic Index (SDI) as a proxy for the development status of regions and countries. Findings In 2017, cirrhosis caused more than 1.32 million (95% UI 1.27-1.45) deaths (440000 [416 000-518 000; 33.3%] in females and 883 000 [838 000-967 000; 66.7%] in males) globally, compared with less than 899 000 (829 000-948 000) deaths in 1990. Deaths due to cirrhosis constituted 2.4% (2.3-2.6) of total deaths globally in 2017 compared with 1.9% (1.8-2.0) in 1990. Despite an increase in the number of deaths, the age-standardised death rate decreased from 21.0 (19.2-22.3) per 100 000 population in 1990 to 16.5 (15.8-18-1) per 100 000 population in 2017. Sub-Saharan Africa had the highest age-standardised death rate among GBD super-regions for all years of the study period (32.2 [25.8-38.6] deaths per 100 000 population in 2017), and the high-income super-region had the lowest (10.1 [9.8-10-5] deaths per 100 000 population in 2017). The age-standardised death rate decreased or remained constant from 1990 to 2017 in all GBD regions except eastern Europe and central Asia, where the age-standardised death rate increased, primarily due to increases in alcohol-related liver disease prevalence. At the national level, the age-standardised death rate of cirrhosis was lowest in Singapore in 2017 (3.7 [3.3-4.0] per 100 000 in 2017) and highest in Egypt in all years since 1990 (103.3 [64.4-133.4] per 100 000 in 2017). There were 10.6 million (10.3-10.9) prevalent cases of decompensated cirrhosis and 112 million (107-119) prevalent cases of compensated cirrhosis globally in 2017. There was a significant increase in age-standardised prevalence rate of decompensated cirrhosis between 1990 and 2017. Cirrhosis caused by NASH had a steady age-standardised death rate throughout the study period, whereas the other four causes showed declines in age-standardised death rate. The age-standardised prevalence of compensated and decompensated cirrhosis due to NASH increased more than for any other cause of cirrhosis (by 33.2% for compensated cirrhosis and 54.8% for decompensated cirrhosis) over the study period. From 1990 to 2017, the number of prevalent cases snore than doubled for compensated cirrhosis due to NASH and more than tripled for decompensated cirrhosis due to NASH. In 2017, age-standardised death and DALY rates were lower among countries and territories with higher SDI. Interpretation Cirrhosis imposes a substantial health burden on many countries and this burden has increased at the global level since 1990, partly due to population growth and ageing. Although the age-standardised death and DALY rates of cirrhosis decreased from 1990 to 2017, numbers of deaths and DALYs and the proportion of all global deaths due to cirrhosis increased. Despite the availability of effective interventions for the prevention and treatment of hepatitis B and C, they were still the main causes of cirrhosis burden worldwide, particularly in low-income countries. The impact of hepatitis B and C is expected to be attenuated and overtaken by that of NASH in the near future. Cost-effective interventions are required to continue the prevention and treatment of viral hepatitis, and to achieve early diagnosis and prevention of cirrhosis due to alcohol-related liver disease and NASH.
  •  
9.
  •  
10.
  • Micah, Angela E., et al. (author)
  • Tracking development assistance for health and for COVID-19 : a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990-2050
  • 2021
  • In: The Lancet. - : Elsevier. - 0140-6736 .- 1474-547X. ; 398:10308, s. 1317-1343
  • Research review (peer-reviewed)abstract
    • Background The rapid spread of COVID-19 renewed the focus on how health systems across the globe are financed, especially during public health emergencies. Development assistance is an important source of health financing in many low-income countries, yet little is known about how much of this funding was disbursed for COVID-19. We aimed to put development assistance for health for COVID-19 in the context of broader trends in global health financing, and to estimate total health spending from 1995 to 2050 and development assistance for COVID-19 in 2020. Methods We estimated domestic health spending and development assistance for health to generate total health-sector spending estimates for 204 countries and territories. We leveraged data from the WHO Global Health Expenditure Database to produce estimates of domestic health spending. To generate estimates for development assistance for health, we relied on project-level disbursement data from the major international development agencies' online databases and annual financial statements and reports for information on income sources. To adjust our estimates for 2020 to include disbursements related to COVID-19, we extracted project data on commitments and disbursements from a broader set of databases (because not all of the data sources used to estimate the historical series extend to 2020), including the UN Office of Humanitarian Assistance Financial Tracking Service and the International Aid Transparency Initiative. We reported all the historic and future spending estimates in inflation-adjusted 2020 US$, 2020 US$ per capita, purchasing-power parity-adjusted US$ per capita, and as a proportion of gross domestic product. We used various models to generate future health spending to 2050. Findings In 2019, health spending globally reached $8. 8 trillion (95% uncertainty interval [UI] 8.7-8.8) or $1132 (1119-1143) per person. Spending on health varied within and across income groups and geographical regions. Of this total, $40.4 billion (0.5%, 95% UI 0.5-0.5) was development assistance for health provided to low-income and middle-income countries, which made up 24.6% (UI 24.0-25.1) of total spending in low-income countries. We estimate that $54.8 billion in development assistance for health was disbursed in 2020. Of this, $13.7 billion was targeted toward the COVID-19 health response. $12.3 billion was newly committed and $1.4 billion was repurposed from existing health projects. $3.1 billion (22.4%) of the funds focused on country-level coordination and $2.4 billion (17.9%) was for supply chain and logistics. Only $714.4 million (7.7%) of COVID-19 development assistance for health went to Latin America, despite this region reporting 34.3% of total recorded COVID-19 deaths in low-income or middle-income countries in 2020. Spending on health is expected to rise to $1519 (1448-1591) per person in 2050, although spending across countries is expected to remain varied. Interpretation Global health spending is expected to continue to grow, but remain unequally distributed between countries. We estimate that development organisations substantially increased the amount of development assistance for health provided in 2020. Continued efforts are needed to raise sufficient resources to mitigate the pandemic for the most vulnerable, and to help curtail the pandemic for all. Copyright (C) 2021 The Author(s). Published by Elsevier Ltd.
  •  
11.
  • Niemi, MEK, et al. (author)
  • 2021
  • swepub:Mat__t
  •  
12.
  • Kanai, M, et al. (author)
  • 2023
  • swepub:Mat__t
  •  
13.
  • Abbara, Aula, et al. (author)
  • The challenges of tuberculosis control in protracted conflict: The case of Syria
  • 2020
  • In: International Journal of Infectious Diseases. - : Elsevier. - 1201-9712 .- 1878-3511. ; 90, s. 53-59
  • Research review (peer-reviewed)abstract
    • Objectives: Syria's protracted conflict has resulted in ideal conditions for the transmission of tuberculosis (TB) and the cultivation of drug-resistant strains. This paper compares TB control in Syria before and after the conflict using available data, examines the barriers posed by protracted conflict and those specific to Syria, and discusses what measures can be taken to address the control of TB in Syria.Results: Forced mass displacement and systematic violations of humanitarian law have resulted in overcrowding and the destruction of key infrastructure, leading to an increased risk of both drug-sensitive and resistant TB, while restricting the ability to diagnose, trace contacts, treat, and follow-up. Pre-conflict, TB in Syria was officially reported at 22 per 100 000 population; the official figure for 2017 of 19 per 100 000 is likely a vast underestimate given the challenges and barriers to case detection. Limited diagnostics also affect the diagnosis of multidrug- and rifampicin-resistant TB, reported as comprising 8.8% of new diagnoses in 2017.Conclusions: The control of TB in Syria requires a multipronged, tailored, and pragmatic approach to improve timely diagnosis, increase detection, stop transmission, and mitigate the risk of drug resistance. Solutions must also consider vulnerable populations such as imprisoned and besieged communities where the risk of drug resistance is particularly high, and must recognize the limitations of national programming. Strengthening capacity to control TB in Syria with particular attention to these factors will positively impact other parallel conditions; this is key as attention turns to post-conflict reconstruction.
  •  
14.
  • Abuhussain, Mohammed Awad, et al. (author)
  • Data-driven approaches for strength prediction of alkali-activated composites
  • 2024
  • In: Case Studies in Construction Materials. - : Elsevier. - 2214-5095. ; 20
  • Journal article (peer-reviewed)abstract
    • Alkali-activated composites (AACs) have attracted considerable interest as a promising alternative to reduce CO2 emissions from Portland cement production and advance the decarbonisation of concrete construction. This study describes the data-driven predictive modelling to anticipate the compressive strength (CS) of AACs. Four different modelling techniques have been chosen to forecast the CS of AACs using the selected data set. The decision tree (DT), multi-layer perceptron (MLP), bagging regressor (BR), and AdaBoost regressor (AR) were employed to investigate the precision level of each model. When it comes to predicting the CS of AACs, the results show that the AR model performs better than the BR model, the MLP model, and the DT model by providing a higher value for the coefficient of determination, which is equal to 0.91, and a lower MAPE value, which is equal to 13.35%. However, the accuracy level of the BR model was very near to that of the AR model, with the R2 value suggesting a value of 0.90 and the MAPE value indicating a value of 14.43%. Moreover, the graphical user interface has also been developed for the strength prediction of alkali-activated composites, making it easy to get the required output from the selected inputs.
  •  
15.
  • Ahmad, Ashfaq, et al. (author)
  • Design, Fabrication, and Measurements of Extended L-Shaped Multiband Antenna for Wireless Applications
  • 2018
  • In: Applied Computational Electromagnetics Society Journal. - : Applied Computational Electromagnetics Society (ACES). - 1054-4887. ; 33:4, s. 388-393
  • Journal article (peer-reviewed)abstract
    • This article expounds a multi-band compact shaped antenna, which is based on CPW ground plane. FR-4 with a thickness of 1.6 mm is used as a substrate for the proposed antenna. The proposed antenna is capable of operating at 1.56 GHz for (Global Positioning System), 2.45 GHz (Wireless Local Area Network) and 4.49 GHz (Aeronautical Mobile Telemetry (AMT) fixed services). The efficiency at 1.56, 2.45, and 4.49 GHz is 79.7, 76.9 and 76.7%, respectively. The VSWR of the presented antenna is less than 1.5 at all the desired resonance modes, which confirms its good impedance matching. The performance of the proposed antenna is evaluated in terms of VSWR, return loss, radiation pattern and efficiency. CST (R) MWS (R) software is used for simulations. In order to validate the simulation results, a prototype of the designed antenna is fabricated and a good agreement is found between the simulated and measured results.
  •  
16.
  • Ahmad, Ashfaq, et al. (author)
  • Flexible and Compact Spiral-Shaped Frequency Reconfigurable Antenna for Wireless Applications
  • 2020
  • In: IETE Journal of Research. - : TAYLOR & FRANCIS LTD. - 0377-2063 .- 0974-780X. ; 66:1, s. 22-29
  • Journal article (peer-reviewed)abstract
    • A flexible, spiral-shaped frequency reconfigurable antenna with a compact size (20 x 24 mm(2)) is presented. The proposed antenna has a low-profile planar structure and is able to operate at five different frequency bands, i.e., 4.19-4.48, 5.98-6.4, 3.42-4.0, 5.4-5.68, and 6.8-7.0 GHz. The multiband operation enables the antenna to cover aeronautical radio navigation, fixed satellite communication, WLAN, and WiMAX standards. A radiating element is backed by Rogers (R) 5880 substrate with a thickness of 0.508 mm and dielectric constant of 2.2. The spiral shape is achieved by introducing different strips. Frequency reconfiguration is achieved by the incorporation of a lumped element in a strip, so that the antenna can switch between different resonances. To validate the performance of the antenna, the prototype of the design was fabricated and tested. Good acquiescent is seen between simulated and measured results. The proposed antenna operates efficiently with appreciable return loss, directivity, bandwidth, and peak gain.
  •  
17.
  • Ahmad, Amais, et al. (author)
  • IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4 : Prediction accuracy and software comparisons with improved data and modelling strategies
  • 2020
  • In: European journal of pharmaceutics and biopharmaceutics. - : Elsevier BV. - 0939-6411 .- 1873-3441. ; 156, s. 50-63
  • Journal article (peer-reviewed)abstract
    • Oral drug absorption is a complex process depending on many factors, including the physicochemical properties of the drug, formulation characteristics and their interplay with gastrointestinal physiology and biology. Physiological-based pharmacokinetic (PBPK) models integrate all available information on gastro-intestinal system with drug and formulation data to predict oral drug absorption. The latter together with in vitro-in vivo extrapolation and other preclinical data on drug disposition can be used to predict plasma concentration-time profiles in silico. Despite recent successes of PBPK in many areas of drug development, an improvement in their utility for evaluating oral absorption is much needed. Current status of predictive performance, within the confinement of commonly available in vitro data on drugs and formulations alongside systems information, were tested using 3 PBPK software packages (GI-Sim (ver.4.1), Simcyp® Simulator (ver.15.0.86.0), and GastroPlusTM (ver.9.0.00xx)). This was part of the Innovative Medicines Initiative (IMI) Oral Biopharmaceutics Tools (OrBiTo) project.Fifty eight active pharmaceutical ingredients (APIs) were qualified from the OrBiTo database to be part of the investigation based on a priori set criteria on availability of minimum necessary information to allow modelling exercise. The set entailed over 200 human clinical studies with over 700 study arms. These were simulated using input parameters which had been harmonised by a panel of experts across different software packages prior to conduct of any simulation. Overall prediction performance and software packages comparison were evaluated based on performance indicators (Fold error (FE), Average fold error (AFE) and absolute average fold error (AAFE)) of pharmacokinetic (PK) parameters.On average, PK parameters (Area Under the Concentration-time curve (AUC0-tlast), Maximal concentration (Cmax), half-life (t1/2)) were predicted with AFE values between 1.11 and 1.97. Variability in FEs of these PK parameters was relatively high with AAFE values ranging from 2.08 to 2.74. Around half of the simulations were within the 2-fold error for AUC0-tlast and around 90% of the simulations were within 10-fold error for AUC0-tlast. Oral bioavailability (Foral) predictions, which were limited to 19 APIs having intravenous (i.v.) human data, showed AFE and AAFE of values 1.37 and 1.75 respectively. Across different APIs, AFE of AUC0-tlast predictions were between 0.22 and 22.76 with 70% of the APIs showing an AFE > 1. When compared across different formulations and routes of administration, AUC0-tlast for oral controlled release and i.v. administration were better predicted than that for oral immediate release formulations. Average predictive performance did not clearly differ between software packages but some APIs showed a high level of variability in predictive performance across different software packages. This variability could be related to several factors such as compound specific properties, the quality and availability of information, and errors in scaling from in vitro and preclinical in vivo data to human in vivo behaviour which will be explored further. Results were compared with previous similar exercise when the input data selection was carried by the modeller rather than a panel of experts on each in vitro test. Overall, average predictive performance was increased as reflected in smaller AAFE value of 2.8 as compared to AAFE value of 3.8 in case of previous exercise.
  •  
18.
  • Ahmad, S. A., et al. (author)
  • Penta-band antenna with defected ground structure for wireless communication applications
  • 2019
  • In: 2019 2nd International Conference on Computing, Mathematics and Engineering Technologies, iCoMET 2019. - : Institute of Electrical and Electronics Engineers Inc.. - 9781538695098
  • Conference paper (peer-reviewed)abstract
    • This work proposes a compact, penta-band, slotted antenna with Defected Ground Structure (DGS). The proposed multiband resonator is intended for integration into microwave circuits and portable RF portable devices. The prototype with spurlines and DGS is designed on thin Rogers RT Duroid 5880 substrate having thickness 0.508 mm. The presented radiator is capable to cover the frequency bands 2.46-2.59 GHz, 2.99-3.78 GHz, 5.17-5.89 GHz, 6.86-7.36 GHz, 9.38-11 GHz. The impedance bandwidths of 5.24%, 23.68%, 12.8%, 7.24% and 16.08% is obtained for the covered frequency bands respectively. The antenna proposed in this work thus supports WLAN, WiMAX, ISM, LTE, Bluetooth, C-band and X-band applications. The radiator attains 4.2 dB peak gain. It is apparent from the radiation performance of the prototype, that it is an effective candidate for current and forthcoming multiband wireless applications.
  •  
19.
  • Ahmad, Shahzad, et al. (author)
  • CDH6 and HAGH protein levels in plasma associate with Alzheimer’s disease in APOE ε4 carriers
  • 2020
  • In: Scientific Reports. - : Springer Science and Business Media LLC. - 2045-2322. ; 10:1
  • Journal article (peer-reviewed)abstract
    • Many Alzheimer’s disease (AD) genes including Apolipoprotein E (APOE) are found to be expressed in blood-derived macrophages and thus may alter blood protein levels. We measured 91 neuro-proteins in plasma from 316 participants of the Rotterdam Study (incident AD = 161) using Proximity Extension Ligation assay. We studied the association of plasma proteins with AD in the overall sample and stratified by APOE. Findings from the Rotterdam study were replicated in 186 AD patients of the BioFINDER study. We further evaluated the correlation of these protein biomarkers with total tau (t-tau), phosphorylated tau (p-tau) and amyloid-beta (Aβ) 42 levels in cerebrospinal fluid (CSF) in the Amsterdam Dementia Cohort (N = 441). Finally, we conducted a genome-wide association study (GWAS) to identify the genetic variants determining the blood levels of AD-associated proteins. Plasma levels of the proteins, CDH6 (β = 0.638, P = 3.33 × 10−4) and HAGH (β = 0.481, P = 7.20 × 10−4), were significantly elevated in APOE ε4 carrier AD patients. The findings in the Rotterdam Study were replicated in the BioFINDER study for both CDH6 (β = 1.365, P = 3.97 × 10−3) and HAGH proteins (β = 0.506, P = 9.31 × 10−7) when comparing cases and controls in APOE ε4 carriers. In the CSF, CDH6 levels were positively correlated with t-tau and p-tau in the total sample as well as in APOE ε4 stratum (P < 1 × 10−3). The HAGH protein was not detected in CSF. GWAS of plasma CDH6 protein levels showed significant association with a cis-regulatory locus (rs111283466, P = 1.92 × 10−9). CDH6 protein is implicated in cell adhesion and synaptogenesis while HAGH protein is related to the oxidative stress pathway. Our findings suggest that these pathways may be altered during presymptomatic AD and that CDH6 and HAGH may be new blood-based biomarkers.
  •  
20.
  • Ali, Amjad, et al. (author)
  • A potential electrolyte (Ce1-x CaxO2-delta) for fuel cells:Theoretical andexperimental study
  • 2018
  • In: Ceramics International. - : ELSEVIER SCI LTD. - 0272-8842 .- 1873-3956. ; 44:11, s. 12676-12683
  • Journal article (peer-reviewed)abstract
    • First-principles calculations are performed using density function theory to explore the effects of dopant Ca in ceria (Ce1-x CaxO2-delta). The impact of oxygen vacancy on band gap and density of states is examined in doped ceria using generalized gradient approximations. Vacancy association and vacancy formation energies of the doped ceria are calculated to reveal the effect of dopant on ion conduction. The experimental study of the sample Ce0.875Ca0.125O2-delta) was performed to compare with the theoretical results. The obtained results from theoretical calculation and experimental techniques show that oxygen vacancy increases the volume, lattice constant (5.47315 angstrom) but decrease the band gap (1.72 eV) and bulk modulus. The dopant radius (1.173 angstrom) and lattice constant (5.4718 angstrom) are also calculated by equations which is close to the DFT lattice parameter. The result shows that oxygen vacancy shifts the density of states to lower energy region. Band gap is decreased due to shifting of valence states to conduction band. Vacancy formation shows a significance increase in density of states near the Fermi level. Density of states at Fermi level is proportional to the conductivity, so an increase in density of states near the Fermi level increases the conductivity. The experimental measured ionic conductivity is found to 0.095 S cm(-1) at 600 degrees C. The microstructural studies is also reported in this work.
  •  
21.
  •  
22.
  • Bahrami, Mohammad Amin, et al. (author)
  • Numerical investigation of hydrodynamic damping of a pitching hydrofoil at different flow regimes
  • 2024
  • In: The 17th Asian International Conference on Fluid Machinery (AICFM 17 2023) 20/10/2023 - 23/10/2023 Zhenjiang, China. - : Institute of Physics (IOP).
  • Conference paper (peer-reviewed)abstract
    • Due to the development of intermittent renewable energy resources, hydropower plants are mostly operated under off-design conditions. This may lead to natural frequency excitation shortening the turbine life-span. To accurately estimate the fatigue life, it is necessary to evaluate the hydrodynamic damping parameters. In the present study, different flow regimes and their relationship with hydrodynamic damping are analyzed numerically using the 3 - Reθt transition SST ĸ - ω turbulence model. The test case is a NACA0009 hydrofoil pitching around its center of mass. A good agreement between the present and previous numerical results is obtained. Consistent with the literature, hydrodynamic damping coefficient demonstrate consistently two different regions. The phase shift between the displacement and moment increases with the rise of the pitching frequency. After reaching a peak value at a reduced frequency of around κ = 5, the phase shift starts to decrease, and eventually approaches zero again. The damping behavior demonstrates an opposite trend. First, it reduces in spite of the phase shift increase, and after the inflection point, where the flow field changes from the drag mode to the thrust mode, it rises due to the torque development. The maximum of the damping occurs at the low frequencies.
  •  
23.
  •  
24.
  • Bellenguez, C, et al. (author)
  • New insights into the genetic etiology of Alzheimer's disease and related dementias
  • 2022
  • In: Nature genetics. - : Springer Science and Business Media LLC. - 1546-1718 .- 1061-4036. ; 54:4, s. 412-436
  • Journal article (peer-reviewed)abstract
    • Characterization of the genetic landscape of Alzheimer’s disease (AD) and related dementias (ADD) provides a unique opportunity for a better understanding of the associated pathophysiological processes. We performed a two-stage genome-wide association study totaling 111,326 clinically diagnosed/‘proxy’ AD cases and 677,663 controls. We found 75 risk loci, of which 42 were new at the time of analysis. Pathway enrichment analyses confirmed the involvement of amyloid/tau pathways and highlighted microglia implication. Gene prioritization in the new loci identified 31 genes that were suggestive of new genetically associated processes, including the tumor necrosis factor alpha pathway through the linear ubiquitin chain assembly complex. We also built a new genetic risk score associated with the risk of future AD/dementia or progression from mild cognitive impairment to AD/dementia. The improvement in prediction led to a 1.6- to 1.9-fold increase in AD risk from the lowest to the highest decile, in addition to effects of age and the APOE ε4 allele.
  •  
25.
  • Belloy, Michael E., et al. (author)
  • Challenges at the APOE locus : a robust quality control approach for accurate APOE genotyping
  • 2022
  • In: Alzheimer's Research & Therapy. - : Springer Nature. - 1758-9193. ; 14:1
  • Journal article (peer-reviewed)abstract
    • Background: Genetic variants within the APOE locus may modulate Alzheimer's disease (AD) risk independently or in conjunction with APOE*2/3/4 genotypes. Identifying such variants and mechanisms would importantly advance our understanding of APOE pathophysiology and provide critical guidance for AD therapies aimed at APOE. The APOE locus however remains relatively poorly understood in AD, owing to multiple challenges that include its complex linkage structure and uncertainty in APOE*2/3/4 genotype quality. Here, we present a novel APOE*2/3/4 filtering approach and showcase its relevance on AD risk association analyses for the rs439401 variant, which is located 1801 base pairs downstream of APOE and has been associated with a potential regulatory effect on APOE.Methods: We used thirty-two AD-related cohorts, with genetic data from various high-density single-nucleotide polymorphism microarrays, whole-genome sequencing, and whole-exome sequencing. Study participants were filtered to be ages 60 and older, non-Hispanic, of European ancestry, and diagnosed as cognitively normal or AD (n = 65,701). Primary analyses investigated AD risk in APOE*4/4 carriers. Additional supporting analyses were performed in APOE*3/4 and 3/3 strata. Outcomes were compared under two different APOE*2/3/4 filtering approaches.Results: Using more conventional APOE*2/3/4 filtering criteria (approach 1), we showed that, when in-phase with APOE*4, rs439401 was variably associated with protective effects on AD case-control status. However, when applying a novel filter that increases the certainty of the APOE*2/3/4 genotypes by applying more stringent criteria for concordance between the provided APOE genotype and imputed APOE genotype (approach 2), we observed that all significant effects were lost. Conclusions: We showed that careful consideration of APOE genotype and appropriate sample filtering were crucial to robustly interrogate the role of the APOE locus on AD risk. Our study presents a novel APOE filtering approach and provides important guidelines for research into the APOE locus, as well as for elucidating genetic interaction effects with APOE*2/3/4.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-25 of 63
Type of publication
journal article (48)
conference paper (5)
other publication (3)
research review (2)
Type of content
peer-reviewed (52)
other academic/artistic (6)
Author/Editor
Ahmad, S. (14)
Williams, J (8)
Marshall, R. (7)
Ruiz, A. (7)
Khan, A. (7)
Biondi, A (7)
show more...
Fischer, F (7)
Khan, M (7)
Singh, A (7)
Davies, E. (6)
Gupta, R. (6)
De Deyn, PP (6)
Mukherjee, S. (6)
Song, Y. (6)
Aljunid, SM (6)
Arabloo, J (6)
Badiye, AD (6)
Basu, S (6)
Bhagavathula, AS (6)
Burkart, K (6)
Golechha, M (6)
Hassan, A (6)
Hay, SI (6)
Holla, R (6)
Hosseinzadeh, M (6)
Hostiuc, S (6)
Jakovljevic, M (6)
Jonas, JB (6)
Jurisson, M (6)
Kabir, A (6)
Kalankesh, LR (6)
Lasrado, S (6)
Majeed, A (6)
Malta, DC (6)
Mansournia, MA (6)
Menezes, RG (6)
Mirrakhimov, EM (6)
Mohammed, S (6)
Mokdad, AH (6)
Monasta, L (6)
Nangia, V (6)
Negoi, I (6)
Olagunju, AT (6)
Samy, AM (6)
Santric-Milicevic, M ... (6)
Sathian, B (6)
Shaikh, MA (6)
Tovani-Palone, MR (6)
Waheed, Y (6)
Wang, YZ (6)
show less...
University
Karolinska Institutet (30)
Uppsala University (18)
Royal Institute of Technology (12)
Umeå University (10)
Stockholm University (9)
University of Gothenburg (7)
show more...
Lund University (7)
Luleå University of Technology (4)
Örebro University (2)
Mid Sweden University (2)
Högskolan Dalarna (2)
University of Gävle (1)
show less...
Language
English (63)
Research subject (UKÄ/SCB)
Medical and Health Sciences (33)
Natural sciences (11)
Engineering and Technology (10)
Agricultural Sciences (1)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view